Loading...
XNAS
OCGN
Market cap494mUSD
Jul 09, Last price  
1.47USD
1D
-2.00%
1Q
-16.48%
Jan 2017
-98.53%
IPO
-99.78%
Name

Ocugen Inc

Chart & Performance

D1W1MN
XNAS:OCGN chart
P/E
—
P/S
112.76
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.74%
Rev. gr., 5y
152.50%
Revenues
4m
+8.83%
26,0008,00000000043,00002,488,0006,036,0004,055,0004,413,000
Net income
-68m
L+25.52%
-16,935,000-25,712,000-22,793,000-32,024,000-16,208,000-26,414,000-8,643,000-20,243,000-21,822,000-58,365,000-86,804,000-63,078,000-54,054,000-67,846,000
CFO
-57m
L+35.17%
-12,232,000-15,282,000-18,405,000-30,034,000-25,736,000-23,020,000-15,777,000-16,893,281-14,708,730-47,941,000-60,079,000-62,054,000-42,142,000-56,964,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
URL
https://ocugen.com/
IPO date
Dec 03, 2014
Employees
84
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT